Answers are grounded in this paper and cite their sources.
As therapy of cancer becomes more sucessful, the number of long-term survivors is increasing. In addition, cancer chemotherapeutic drugs are being used as immunosuppressive agents in the chronic treatment of non-neoplastic diseases. The long-range hazards of therapy are a serious consideration in these two groups of patients. This brief review examines the potential oncogenic as well as co-oncogenic hazards of cancer chemotherapy in man. Many of these drugs are oncogenic and/or co-oncogenic in experimental animals.
No takes yet. Share an insight, caveat, or question.
Curtis C. Harris (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: